Citron's Left Said to Take New Short Stake in Valeant Pharma (VRX); Says Worth $0
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- S&P 500, Nasdaq futures slip as investors eye SK Hynix listing, Middle East risks
- Oil heads for weekly gain as Middle East supply risks persist
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Valeant (VRX) Investors Should Be Focused on Earnings Not Upcoming Product Catalysts - Wells Fargo
July 14, 2016 1:29 PM EDTWhile Valeant Pharmaceuticals (NYSE: VRX) continues to avoid trading on fundamentals three potential catalysts lie ahead for the company. Today, Wells Fargo bearish-leaning analyst David Maris provide his thoughts ahead of these events.
The 3 events are:
Friday (7/15) advisory panel documents should become available ahead of next Tuesdays (7/19) FDA advisory panel on brodalumab;next... MoreCitron Research calling Valeant Pharma (VRX) a zero
July 13, 2016 12:48 PM EDTCitron Research calling Valeant Pharma (NYSE: VRX) a zero
Have Valeant Pharma (VRX) Shareholders Finally Capitulated?
July 13, 2016 12:24 PM EDTValeant Pharma (NYSE: VRX) is gaining as earlier reported liquidation at Sequoia Fund and news that ex-CEO... More
Valeant Pharma (VRX) Pearson Said to Have Sold 5M Shares - CNBC
July 13, 2016 11:28 AM EDTCNBC Scott Wapner reports Valeant Pharma (NYSE: VRX) Pearson unloaded much more of his holdings than originally thought. Nearly 5m shares and in the money options worth $96.8m.
... More
Citron's Left to go short on Valeant again: TheStreet
July 13, 2016 9:20 AM EDT(Reuters) - Andrew Left, who runs short-selling firm Citron Research, is planning to take a short position in Valeant Pharmaceuticals International Inc again, TheStreet reported.
Left's comments come a day after Sequoia Fund, which once was Valeant's largest shareholder, said it exited its position in the embattled Canadian drugmaker last month.
"They've sat down, and they've seen and they've interviewed and they walked," Left told TheStreet in an interview, adding that... More
RBC Highlights Next Week's Key Events for Valeant Pharma (VRX)
July 13, 2016 8:19 AM EDTRBC affirms Valeant Pharma (NYSE: VRX) at Sector Perform with a price target of $33 as the firm provides a schedule and commentary of what investors should focus on next week for the company.
RBC analyst Douglas Miehm noted:
Upcoming PDUFA dates: Oral Relistor (July 19) and latanoprostene bunod (July 21). Valeant has two PDUFA dates next week. The first, on July 19, is for Oral Relistor for the treatment of opioid-induced constipation. Following the FDA's delay in PDUFA date, we remain confident that Oral Relistor should see approval in or... MoreLong-Time Valeant Pharma (VRX) Holder Sequoia Fund Exits Position
July 13, 2016 6:09 AM EDTValeant Pharma (NYSE: VRX) shares are on watch Wednesday following news that long-time holder Sequoia Fund exited its position.
Valeant Pharma (VRX) volatility at lower end of eight month range, Sequoia Fund exited position
July 13, 2016 6:05 AM EDTValeant Pharma (NYSE: VRX) is recently up 21c to $23.43 in the premarket on Sequoia Fund, the longtime and once the largest investor in Valeant exiting the investment last month. July call option implied volatility is at 82, August is at 86; compared to its 52-week range of 29 to
... More